Research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Dynavax Technologies in a report ...

William Blair reduced their Q1 2025 earnings per share estimates for AAON in a note issued to investors on Thursday, February 20th. William Blair analyst R. Merkel now expects that the construction ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

KYIV, Ukraine-The U.S. and Ukraine pushed divergent messages over the weekend, with Kyiv pressing for better terms to the mineral-rights deal sought by President Trump, while Washington urged Ukraine ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

William Blair analyst Arjun Bhatia maintained a Buy rating on Radcom (RDCM – Research Report) today. The company’s shares opened today at ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...